Shopping Cart 0
Cart Subtotal
AED 0

Europe Myositis Treatment Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 15414

Details

Europe myositis treatment market is projected to register a healthy CAGR of 6.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Europe Myositis Treatment Market, By Type (Polymyositis, Dermatomyositis, Inclusion Body Myositis (IBM), Necrotizing Myopathy, Juvenile Myositis, Others), Treatment (Medication, Therapy, Supplements), End User (Hospitals, Therapy Centers, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Europe myositis treatment market are:

Attractive support and funding

Rising awareness about the disease

Market Players:

The key market players for Europe myositis treatment market are listed below:

CSL Behring (A Subsidiary of CSL)

Takeda Pharmaceutical Company Limited

Hikma Pharmaceuticals PLC

Mylan N.V.

Pfizer Inc.

Amneal Pharmaceuticals LLC

Horizon Therapeutics plc

Grifols, S.A.

Kedrion Biopharma Inc. (A Subsidiary of Kedrion S.p.A)

Halozyme, Inc.

ORPHAZYME A/S

Accord Healthcare

Sandoz AG (A Subsidiary of Novartis AG)

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MYOSITIS TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 EPIDEMIOLOGY

6 EUROPE MYOSITIS TREATMENT MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION

7.1.2 RISING AWARENESS ABOUT THE DISEASE

7.1.3 ATTRACTIVE SUPPORT AND FUNDING

7.1.4 EMERGING BIOLOGICAL THERAPIES

7.1.5 AVAILABILITY OF OFF LABEL DRUGS

7.2 RESTRAINTS

7.2.1 UNAVAILABILITY OF EFFECTIVE TREATMENT FOR INCLUSION BODIES MYOSITIS (IBM)

7.2.2 HIGH COST ASSOCIATED WITH TREATMENT OF MYOSITIS

7.2.3 LACK OF HEALTHCARE EXPENDITURE IN MIDDLE INCOME AND LOW INCOME COUNTRIES

7.3 OPPORTUNITIES

7.3.1 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT

7.3.2 FAVOURABLE REIMBURSEMENT POLICIES

7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.4 PRESENCE OF NOVEL PIPELINE DRUGS

7.4 CHALLENGES

7.4.1 SIDE EFFECTS CAUSED BY CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS DRUGS

7.4.2 EXISTENCE OF HERBAL MEDICINES AND ACUPUNCTURE FOR MYOSITIS TREATMENT

7.4.3 INABILITY TO ACCURATELY DIAGNOSE THE DISEASE SYMPTOMS

8 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE MYOSITIS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON SUPPLY CHAIN

8.3 IMPACT ON DEMAND

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 POLYMYOSITIS

9.3 DERMATOMYOSITIS

9.4 INCLUSION BODY MYOSITIS (IBM)

9.4.1 SPORADIC INCLUSION BODY MYOSITIS (S-IBM)

9.4.2 HEREDITARY INCLUSION BODY MYOPATHY (H-IBM)

9.5 NECROTIZING MYOPATHY

9.6 JUVENILE MYOSITIS

9.7 OTHERS

10 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 MEDICATION

10.2.1 IMMUNOSUPPRESSANTS

10.2.1.1 METHOTREXATE

10.2.1.2 AZATHIOPRINE

10.2.1.3 MYCOPHENOLATE MOFETIL

10.2.1.4 CYCLOPHOSPHAMIDE

10.2.1.5 TACROLIMUS

10.2.1.6 CYCLOSPORINE

10.2.1.7 HYDROXYCHLOROQUINE

10.2.1.8 OTHERS

10.2.2 CORTICOSTEROIDS

10.2.2.1 PREDNISONE

10.2.2.2 PREDNISOLONE

10.2.2.3 METHYLPREDNISOLONE

10.2.2.4 ADRENOCORTICOTROPIC HORMONE (ACTH)

10.2.2.5 OTHERS

10.2.3 IMMUNOGLOBULINS

10.2.3.1 IMMUNE GLOBULINS INTRAVENOUS

10.2.3.2 IMMUNE GLOBULINS SUBCUTANEOUS

10.2.3.3 OTHERS

10.3 THERAPY

10.3.1 PHYSICAL THERAPY

10.3.2 OCCUPATIONAL THERAPY

10.3.3 SPEECH THERAPY

10.3.4 SELF-CARE THERAPY

10.3.5 OTHERS

10.4 SUPPLEMENTS

10.4.1 CREATINE MONOHYDRATE

10.4.2 MITOCHONDRIAL COCKTAIL

10.4.3 OTHERS

11 EUROPE MYOSITIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 THERAPY CENTERS

11.4 SPECIALTY CLINICS

11.5 HOME HEALTHCARE

11.6 OTHERS

12 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 EUROPE MYOSITIS TREATMENT MARKET, BY GEOGRAPHY

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 U.K.

13.1.4 ITALY

13.1.5 NETHERLANDS

13.1.6 SPAIN

13.1.7 RUSSIA

13.1.8 SWITZERLAND

13.1.9 TURKEY

13.1.10 AUSTRIA

13.1.11 NORWAY

13.1.12 HUNGARY

13.1.13 LITHUANIA

13.1.14 IRELAND

13.1.15 POLAND

13.1.16 REST OF EUROPE

14 EUROPE MYOSITIS TREATMENT MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT

16 COMPANY PROFILES

16.1 PFIZER INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 TEVA PHARMACEUTICAL U.S.A INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 MYLAN N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 GRIFOLS, S.A.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 CSL BEHRING (A SUBSIDIARY OF CSL)

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 HIKMA PHARMACEUTICALS PLC

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 AMNEAL PHARMACEUTICALS LLC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.10 KEDRION BIOPHARMA INC. (A SUBSIDIARY OF KEDRION S.P.A)

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 ABCURO, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 ACCORD HEALTHCARE

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

16.13 ADMA BIOLOGICS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENTS

16.14 ALZHEON, INC.

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 BIO PRODUCTS LABORATORY LTD.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 CORBUS PHARMACEUTICALS HOLDINGS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 HALOZYME, INC.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENTS

16.18 HORIZON THERAPEUTICS PLC

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENTS

16.19 ORPHAZYME A/S

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.20 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 EUROPE MYOSITIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE MYOSITIS TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE MYOSITIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE MYOSITIS TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE MYOSITIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE MYOSITIS TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE MYOSITIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE MYOSITIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE MYOSITIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE MYOSITIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION AND RISING AWARENESS ABOUT THE DISEASE IS DRIVING THE EUROPE MYOSITIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 POLYMYOSITIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MYOSITIS TREATMENT MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE MYOSITIS TREATMENT MARKET

FIGURE 14 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, 2019

FIGURE 15 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)

FIGURE 16 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 17 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019

FIGURE 19 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)

FIGURE 20 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)

FIGURE 21 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 22 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, 2019

FIGURE 23 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)

FIGURE 24 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)

FIGURE 25 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 26 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 27 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 28 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 29 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 EUROPE MYOSITIS TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 31 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 32 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 33 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 34 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 35 EUROPE MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%)


List Of Table

LIST OF TABLES

TABLE 1 EUROPE MYOSITIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR MYOSITIS

TABLE 3 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 4 EUROPE POLYMYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 5 EUROPE DERMATOMYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 6 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 8 EUROPE NECROTIZING MYOPATHY IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 EUROPE JUVENILE MYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EUROPE OTHERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT, 2019-2027 (USD MILLION)

TABLE 12 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 14 EUROPE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 15 EUROPE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 16 EUROPE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 17 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 18 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 19 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 20 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 21 EUROPE MYOSITIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 22 EUROPE HOSPITALS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 EUROPE THERAPY CENTERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 EUROPE SPECIALTY CLINICS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 EUROPE HOME HEALTHCARE IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 EUROPE OTHERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 28 EUROPE HOSPITAL PHARMACIES IN MYOSITS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 29 EUROPE RETAIL PHARMACIES IN MYOSITIS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 30 EUROPE ONLINE PHARMACY IN MYOSITS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 31 EUROPE MYOSITIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 32 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 33 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 34 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 35 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 36 EUROPE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 37 EUROPE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 38 EUROPE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 39 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 40 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 41 EUROPE MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 42 ASIA-PACIFIC MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 43 GERMANY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 44 GERMANY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 45 GERMANY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 46 GERMANY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 47 GERMANY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 48 GERMANY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 49 GERMANY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 50 GERMANY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 51 GERMANY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 52 GERMANY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 53 GERMANY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 54 FRANCE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 55 FRANCE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 56 FRANCE MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 57 FRANCE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 58 FRANCE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 59 FRANCE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 60 FRANCE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 61 FRANCE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 62 FRANCE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 63 FRANCE MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 64 FRANCE MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 65 U.K. MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 66 U.K. INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 67 U.K. MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 68 U.K. MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 69 U.K. IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 70 U.K. CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 71 U.K. IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 72 U.K. THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 73 U.K. SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 74 U.K. MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 75 U.K. MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 76 ITALY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 77 ITALY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 78 ITALY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 79 ITALY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 80 ITALY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 81 ITALY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 82 ITALY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 83 ITALY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 84 ITALY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 85 ITALY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 86 ITALY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 87 NETHERLANDS MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 88 NETHERLANDS INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 89 NETHERLANDS MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 90 NETHERLANDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 91 NETHERLANDS IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 92 NETHERLANDS CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 93 NETHERLANDS IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 94 NETHERLANDS THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 95 NETHERLANDS SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 96 NETHERLANDS MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 97 NETHERLANDS MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 98 SPAIN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 99 SPAIN INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 100 SPAIN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 101 SPAIN MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 102 SPAIN IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 103 SPAIN CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 104 SPAIN IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 105 SPAIN THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 106 SPAIN SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 107 SPAIN MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 108 SPAIN MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 109 RUSSIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 110 RUSSIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 111 RUSSIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 112 RUSSIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 113 RUSSIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 114 RUSSIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 115 RUSSIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 116 RUSSIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 117 RUSSIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 118 RUSSIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 119 RUSSIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 120 SWITZERLAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 121 SWITZERLAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 122 SWITZERLAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 123 SWITZERLAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 124 SWITZERLAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 125 SWITZERLAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 126 SWITZERLAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 127 SWITZERLAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 128 SWITZERLAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 129 SWITZERLAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 130 SWITZERLAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 131 TURKEY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 132 TURKEY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 133 TURKEY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 134 TURKEY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 135 TURKEY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 136 TURKEY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 137 TURKEY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 138 TURKEY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 139 TURKEY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 140 TURKEY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 141 TURKEY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 142 AUSTRIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 143 AUSTRIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 144 AUSTRIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 145 AUSTRIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 146 AUSTRIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 147 AUSTRIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 148 AUSTRIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 149 AUSTRIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 150 AUSTRIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 151 AUSTRIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 152 AUSTRIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 153 NORWAY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 154 NORWAY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 155 NORWAY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 156 NORWAY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 157 NORWAY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 158 NORWAY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 159 NORWAY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 160 NORWAY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 161 NORWAY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 162 NORWAY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 163 NORWAY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 164 HUNGARY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 165 HUNGARY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 166 HUNGARY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 167 HUNGARY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 168 HUNGARY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 169 HUNGARY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 170 HUNGARY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 171 HUNGARY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 172 HUNGARY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 173 HUNGARY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 174 HUNGARY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 175 LITHUANIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 176 LITHUANIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 177 LITHUANIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 178 LITHUANIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 179 LITHUANIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 180 LITHUANIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 181 LITHUANIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 182 LITHUANIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 183 LITHUANIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 184 LITHUANIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 185 LITHUANIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 186 IRELAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 187 IRELAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 188 IRELAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 189 IRELAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 190 IRELAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 191 IRELAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 192 IRELAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 193 IRELAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 194 IRELAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 195 IRELAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 196 IRELAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 197 POLAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 198 POLAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 199 POLAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 200 POLAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 201 POLAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 202 POLAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 203 POLAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 204 POLAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 205 POLAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 206 POLAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 207 POLAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 208 REST OF EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

CSL Behring (A Subsidiary of CSL)

Takeda Pharmaceutical Company Limited

Hikma Pharmaceuticals PLC

Mylan N.V.

Pfizer Inc.

Amneal Pharmaceuticals LLC

Horizon Therapeutics plc

Grifols, S.A.

Kedrion Biopharma Inc. (A Subsidiary of Kedrion S.p.A)

Halozyme, Inc.

ORPHAZYME A/S

Accord Healthcare

Sandoz AG (A Subsidiary of Novartis AG)

Company Profile

Company Profile Title

Europe myositis treatment market is projected to register a healthy CAGR of 6.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Europe Myositis Treatment Market, By Type (Polymyositis, Dermatomyositis, Inclusion Body Myositis (IBM), Necrotizing Myopathy, Juvenile Myositis, Others), Treatment (Medication, Therapy, Supplements), End User (Hospitals, Therapy Centers, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Europe myositis treatment market are:

Attractive support and funding

Rising awareness about the disease

Market Players:

The key market players for Europe myositis treatment market are listed below:

CSL Behring (A Subsidiary of CSL)

Takeda Pharmaceutical Company Limited

Hikma Pharmaceuticals PLC

Mylan N.V.

Pfizer Inc.

Amneal Pharmaceuticals LLC

Horizon Therapeutics plc

Grifols, S.A.

Kedrion Biopharma Inc. (A Subsidiary of Kedrion S.p.A)

Halozyme, Inc.

ORPHAZYME A/S

Accord Healthcare

Sandoz AG (A Subsidiary of Novartis AG)

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE MYOSITIS TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 EPIDEMIOLOGY

6 EUROPE MYOSITIS TREATMENT MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION

7.1.2 RISING AWARENESS ABOUT THE DISEASE

7.1.3 ATTRACTIVE SUPPORT AND FUNDING

7.1.4 EMERGING BIOLOGICAL THERAPIES

7.1.5 AVAILABILITY OF OFF LABEL DRUGS

7.2 RESTRAINTS

7.2.1 UNAVAILABILITY OF EFFECTIVE TREATMENT FOR INCLUSION BODIES MYOSITIS (IBM)

7.2.2 HIGH COST ASSOCIATED WITH TREATMENT OF MYOSITIS

7.2.3 LACK OF HEALTHCARE EXPENDITURE IN MIDDLE INCOME AND LOW INCOME COUNTRIES

7.3 OPPORTUNITIES

7.3.1 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT

7.3.2 FAVOURABLE REIMBURSEMENT POLICIES

7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.4 PRESENCE OF NOVEL PIPELINE DRUGS

7.4 CHALLENGES

7.4.1 SIDE EFFECTS CAUSED BY CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS DRUGS

7.4.2 EXISTENCE OF HERBAL MEDICINES AND ACUPUNCTURE FOR MYOSITIS TREATMENT

7.4.3 INABILITY TO ACCURATELY DIAGNOSE THE DISEASE SYMPTOMS

8 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE MYOSITIS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON SUPPLY CHAIN

8.3 IMPACT ON DEMAND

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE

9.1 OVERVIEW

9.2 POLYMYOSITIS

9.3 DERMATOMYOSITIS

9.4 INCLUSION BODY MYOSITIS (IBM)

9.4.1 SPORADIC INCLUSION BODY MYOSITIS (S-IBM)

9.4.2 HEREDITARY INCLUSION BODY MYOPATHY (H-IBM)

9.5 NECROTIZING MYOPATHY

9.6 JUVENILE MYOSITIS

9.7 OTHERS

10 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 MEDICATION

10.2.1 IMMUNOSUPPRESSANTS

10.2.1.1 METHOTREXATE

10.2.1.2 AZATHIOPRINE

10.2.1.3 MYCOPHENOLATE MOFETIL

10.2.1.4 CYCLOPHOSPHAMIDE

10.2.1.5 TACROLIMUS

10.2.1.6 CYCLOSPORINE

10.2.1.7 HYDROXYCHLOROQUINE

10.2.1.8 OTHERS

10.2.2 CORTICOSTEROIDS

10.2.2.1 PREDNISONE

10.2.2.2 PREDNISOLONE

10.2.2.3 METHYLPREDNISOLONE

10.2.2.4 ADRENOCORTICOTROPIC HORMONE (ACTH)

10.2.2.5 OTHERS

10.2.3 IMMUNOGLOBULINS

10.2.3.1 IMMUNE GLOBULINS INTRAVENOUS

10.2.3.2 IMMUNE GLOBULINS SUBCUTANEOUS

10.2.3.3 OTHERS

10.3 THERAPY

10.3.1 PHYSICAL THERAPY

10.3.2 OCCUPATIONAL THERAPY

10.3.3 SPEECH THERAPY

10.3.4 SELF-CARE THERAPY

10.3.5 OTHERS

10.4 SUPPLEMENTS

10.4.1 CREATINE MONOHYDRATE

10.4.2 MITOCHONDRIAL COCKTAIL

10.4.3 OTHERS

11 EUROPE MYOSITIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 THERAPY CENTERS

11.4 SPECIALTY CLINICS

11.5 HOME HEALTHCARE

11.6 OTHERS

12 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 HOSPITAL PHARMACIES

12.3 RETAIL PHARMACIES

12.4 ONLINE PHARMACIES

13 EUROPE MYOSITIS TREATMENT MARKET, BY GEOGRAPHY

13.1 EUROPE

13.1.1 GERMANY

13.1.2 FRANCE

13.1.3 U.K.

13.1.4 ITALY

13.1.5 NETHERLANDS

13.1.6 SPAIN

13.1.7 RUSSIA

13.1.8 SWITZERLAND

13.1.9 TURKEY

13.1.10 AUSTRIA

13.1.11 NORWAY

13.1.12 HUNGARY

13.1.13 LITHUANIA

13.1.14 IRELAND

13.1.15 POLAND

13.1.16 REST OF EUROPE

14 EUROPE MYOSITIS TREATMENT MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

15 SWOT

16 COMPANY PROFILES

16.1 PFIZER INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 TEVA PHARMACEUTICAL U.S.A INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 MYLAN N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 GRIFOLS, S.A.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 CSL BEHRING (A SUBSIDIARY OF CSL)

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 HIKMA PHARMACEUTICALS PLC

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 AMNEAL PHARMACEUTICALS LLC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.10 KEDRION BIOPHARMA INC. (A SUBSIDIARY OF KEDRION S.P.A)

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 ABCURO, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 ACCORD HEALTHCARE

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

16.13 ADMA BIOLOGICS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENTS

16.14 ALZHEON, INC.

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENT

16.15 BIO PRODUCTS LABORATORY LTD.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

16.16 CORBUS PHARMACEUTICALS HOLDINGS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 HALOZYME, INC.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENTS

16.18 HORIZON THERAPEUTICS PLC

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENTS

16.19 ORPHAZYME A/S

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.20 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 EUROPE MYOSITIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE MYOSITIS TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE MYOSITIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE MYOSITIS TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE MYOSITIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE MYOSITIS TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE MYOSITIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE MYOSITIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE MYOSITIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE MYOSITIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION AND RISING AWARENESS ABOUT THE DISEASE IS DRIVING THE EUROPE MYOSITIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 POLYMYOSITIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MYOSITIS TREATMENT MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE MYOSITIS TREATMENT MARKET

FIGURE 14 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, 2019

FIGURE 15 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)

FIGURE 16 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 17 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019

FIGURE 19 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)

FIGURE 20 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)

FIGURE 21 EUROPE MYOSITIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 22 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, 2019

FIGURE 23 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)

FIGURE 24 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)

FIGURE 25 EUROPE MYOSITIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 26 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 27 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 28 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 29 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 EUROPE MYOSITIS TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 31 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 32 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 33 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 34 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 35 EUROPE MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%)


List Of Table

LIST OF TABLES

TABLE 1 EUROPE MYOSITIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR MYOSITIS

TABLE 3 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 4 EUROPE POLYMYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 5 EUROPE DERMATOMYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION 2018-2027 (USD MILLION)

TABLE 6 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 8 EUROPE NECROTIZING MYOPATHY IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 EUROPE JUVENILE MYOSITIS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EUROPE OTHERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT, 2019-2027 (USD MILLION)

TABLE 12 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 14 EUROPE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 15 EUROPE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 16 EUROPE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 17 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 18 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 19 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 20 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 21 EUROPE MYOSITIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 22 EUROPE HOSPITALS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 EUROPE THERAPY CENTERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 EUROPE SPECIALTY CLINICS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 EUROPE HOME HEALTHCARE IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 EUROPE OTHERS IN MYOSITIS TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 EUROPE MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 28 EUROPE HOSPITAL PHARMACIES IN MYOSITS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 29 EUROPE RETAIL PHARMACIES IN MYOSITIS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 30 EUROPE ONLINE PHARMACY IN MYOSITS TREATMENT MARKET, BY REGION, 2019-2027 (USD MILLION)

TABLE 31 EUROPE MYOSITIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 32 EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 33 EUROPE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 34 EUROPE MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 35 EUROPE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 36 EUROPE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 37 EUROPE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 38 EUROPE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 39 EUROPE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 40 EUROPE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 41 EUROPE MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 42 ASIA-PACIFIC MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 43 GERMANY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 44 GERMANY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 45 GERMANY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 46 GERMANY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 47 GERMANY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 48 GERMANY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 49 GERMANY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 50 GERMANY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 51 GERMANY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 52 GERMANY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 53 GERMANY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 54 FRANCE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 55 FRANCE INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 56 FRANCE MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 57 FRANCE MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 58 FRANCE IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 59 FRANCE CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 60 FRANCE IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 61 FRANCE THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 62 FRANCE SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 63 FRANCE MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 64 FRANCE MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 65 U.K. MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 66 U.K. INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 67 U.K. MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 68 U.K. MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 69 U.K. IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 70 U.K. CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 71 U.K. IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 72 U.K. THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 73 U.K. SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 74 U.K. MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 75 U.K. MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 76 ITALY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 77 ITALY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 78 ITALY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 79 ITALY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 80 ITALY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 81 ITALY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 82 ITALY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 83 ITALY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 84 ITALY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 85 ITALY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 86 ITALY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 87 NETHERLANDS MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 88 NETHERLANDS INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 89 NETHERLANDS MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 90 NETHERLANDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 91 NETHERLANDS IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 92 NETHERLANDS CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 93 NETHERLANDS IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 94 NETHERLANDS THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 95 NETHERLANDS SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 96 NETHERLANDS MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 97 NETHERLANDS MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 98 SPAIN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 99 SPAIN INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 100 SPAIN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 101 SPAIN MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 102 SPAIN IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 103 SPAIN CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 104 SPAIN IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 105 SPAIN THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 106 SPAIN SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 107 SPAIN MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 108 SPAIN MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 109 RUSSIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 110 RUSSIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 111 RUSSIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 112 RUSSIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 113 RUSSIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 114 RUSSIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 115 RUSSIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 116 RUSSIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 117 RUSSIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 118 RUSSIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 119 RUSSIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 120 SWITZERLAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 121 SWITZERLAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 122 SWITZERLAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 123 SWITZERLAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 124 SWITZERLAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 125 SWITZERLAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 126 SWITZERLAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 127 SWITZERLAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 128 SWITZERLAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 129 SWITZERLAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 130 SWITZERLAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 131 TURKEY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 132 TURKEY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 133 TURKEY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 134 TURKEY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 135 TURKEY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 136 TURKEY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 137 TURKEY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 138 TURKEY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 139 TURKEY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 140 TURKEY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 141 TURKEY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 142 AUSTRIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 143 AUSTRIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 144 AUSTRIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 145 AUSTRIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 146 AUSTRIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 147 AUSTRIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 148 AUSTRIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 149 AUSTRIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 150 AUSTRIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 151 AUSTRIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 152 AUSTRIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 153 NORWAY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 154 NORWAY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 155 NORWAY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 156 NORWAY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 157 NORWAY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 158 NORWAY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 159 NORWAY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 160 NORWAY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 161 NORWAY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 162 NORWAY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 163 NORWAY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 164 HUNGARY MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 165 HUNGARY INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 166 HUNGARY MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 167 HUNGARY MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 168 HUNGARY IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 169 HUNGARY CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 170 HUNGARY IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 171 HUNGARY THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 172 HUNGARY SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 173 HUNGARY MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 174 HUNGARY MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 175 LITHUANIA MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 176 LITHUANIA INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 177 LITHUANIA MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 178 LITHUANIA MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 179 LITHUANIA IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 180 LITHUANIA CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 181 LITHUANIA IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 182 LITHUANIA THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 183 LITHUANIA SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 184 LITHUANIA MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 185 LITHUANIA MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 186 IRELAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 187 IRELAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 188 IRELAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 189 IRELAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 190 IRELAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 191 IRELAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 192 IRELAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 193 IRELAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 194 IRELAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 195 IRELAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 196 IRELAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 197 POLAND MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 198 POLAND INCLUSION BODY MYOSITIS (IBM) IN MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

TABLE 199 POLAND MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 200 POLAND MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 201 POLAND IMMUNOSUPPRESSANTS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 202 POLAND CORTICOSTEROIDS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 203 POLAND IMMUNOGLOBULINS MEDICATION IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 204 POLAND THERAPY IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 205 POLAND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY TREATMENT 2018-2027 (USD MILLION)

TABLE 206 POLAND MYOSITIS TREATMENT MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 207 POLAND MEDICATION AND SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (USD MILLION)

TABLE 208 REST OF EUROPE MYOSITIS TREATMENT MARKET, BY TYPE 2018-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

CSL Behring (A Subsidiary of CSL)

Takeda Pharmaceutical Company Limited

Hikma Pharmaceuticals PLC

Mylan N.V.

Pfizer Inc.

Amneal Pharmaceuticals LLC

Horizon Therapeutics plc

Grifols, S.A.

Kedrion Biopharma Inc. (A Subsidiary of Kedrion S.p.A)

Halozyme, Inc.

ORPHAZYME A/S

Accord Healthcare

Sandoz AG (A Subsidiary of Novartis AG)